​

Crescent Biopharma Stock (NASDAQ:CBIO)

ForecastOwnershipFinancialsChart
Crescent Biopharma by TradingView

Previous Close

$18.17

52W Range

$8.72 - $29.00

50D Avg

$12.53

200D Avg

$12.82

Market Cap

$495.75M

Avg Vol (3M)

$212.45K

Beta

1.03

Div Yield

-

CBIO Company Profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

41

IPO Date

Jan 10, 2014

Website

CBIO Performance

CBIO Financial Summary

Dec 25Dec 24Dec 23
Revenue--$10.00K
Operating Income$-152.63M$-68.76M$-39.28M
Net Income$-149.94M$-71.47M$-36.90M
EBITDA$-152.63M-$-39.12M
Basic EPS$-12.82K$-0.59$-0.58
Diluted EPS$-12.82K$-0.59$-0.58

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 24May 06, 24 | 12:00 AM
Q4 23Mar 27, 24 | 8:30 AM
Q3 23Nov 03, 23 | 8:30 AM

Peer Comparison

TickerCompany
IMDXInsight Molecular Diagnostics Inc.
HINDVyome Holdings, Inc.
CCCCC4 Therapeutics, Inc.
HRTXHeron Therapeutics, Inc.
TNXPTonix Pharmaceuticals Holding Corp.
OABIOmniAb, Inc.
SGMOSangamo Therapeutics, Inc.
IPHAInnate Pharma S.A.
CGENCompugen Ltd.